beta-catenin/Tcf-4 pathway inhibitors (Pfizer)

N/A

Report date: 2025/03/14 20:00:48
NME

Base Information

Drug Namebeta-catenin/Tcf-4 pathway inhibitors (Pfizer)
Drug Alias NameN/A
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionCatenin beta 1 degraders
TargetsCatenin beta 1
Therapy Area/IndicationsColorectal Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesWyeth Pharmaceuticals Co
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesWyeth Pharmaceuticals CoPfizer Inc
Active IndicationsN/A
Inactive IndicationsColorectal Neoplasms

Other Information

ATC CodeN/A
Related LinksN/A